Actively Recruiting
Purinergic Signaling and the Postmenopausal Heart
Led by Beth Israel Deaconess Medical Center · Updated on 2026-03-20
500
Participants Needed
1
Research Sites
569 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic response to stress. Loss of estrogen functionality in post menopausal women may account for the increased risk of diastolic heart failure. The investigators will explore said pathways using cardiac tissue obtained from patients undergoing cardiac surgery.
CONDITIONS
Official Title
Purinergic Signaling and the Postmenopausal Heart
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients undergoing cardiac surgery under cardiopulmonary bypass
You will not qualify if you...
- Refusal to participate
- Emergency surgery
- Pre-existing heart block
- Preexisting atrial fibrillation
- Redo surgery
- Estrogen or hormone replacement therapy
- History of chronic heart failure
- History of major kidney disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Actively Recruiting
Research Team
R
Robina Matyal, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here